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Context: The liver as an important organ in the body has many essential functions in physiological processes. One of the major activities of liver is drug metabolism. Hepatic dysfunction affecting hepatic physiological activities, especially drug metabolism can cause many problems during anesthesia and administration of different drugs to patients.
Evidence Acquisition: Studies on hepatic disorders and hypnotic anesthetics prescribed in hepatic disorders were included in this review. For this purpose, reliable databases were used.
Results: Anesthesia should be performed with caution in patients with hepatic dysfunction and drugs with long half-life should be avoided in these patients.
Conclusions: A review of the literature on the use of hypnotic drugs in patients with liver dysfunction showed that some hypnotic drugs used during anesthesia could be safely used in patients with impaired liver function. In these patients, certain drugs should be used with caution.
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1. ContextThe liver plays an important role in the physiology of body, such as food and drug metabolism, production of plasma proteins and hemostatic factors, detoxification and elimination of endogenous and exogenous sub-stances (1, 2). Extent of surgery in patients with cirrhosis and chronic liver disease is increasing every day (3).Liver disease is classified into acute and chronic types; the most common causes of acute type in the world are viral infections, alcohol and drug toxicity (A very com-mon cause in developed countries, so that 70% of patients in the UK are related to acetaminophen toxicity) (4). Viral hepatitis types B and C, alcohol consumption, autoim-mune hepatitis and genetic disorders are some major and common causes of chronic liver dysfunction (5).It could be due to increased survival and improved post-operative outcomes in these patients (6). Anesthesia in a patient with liver disease is a controversial condition, even for experienced anesthesiologists (7).Anesthesia reduces mean arterial blood flow in the liver and the amount of oxygen to the liver and it does not cause a problem in healthy people. A mild increase in liver enzymes, alkaline phosphatase and bilirubin are 
commonly seen in surgical procedures, which the situa-tion is seen in general anesthesia and local and spinal an-esthesia (8). However, there is a transient increase in liver enzymes and it does not cause adverse effects in people with normal liver function, but in patients with liver dis-ease results in hepatic impairment (9). It has been shown that cardiac surgery mortality rate is high in patients with liver cirrhosis (10).Recent developments have led to some improvements in surgery and anesthesia and the results for hepatic pa-tients who undergo anesthesia and surgery (7-11). In ad-dition, patients with liver dysfunction have a high risk of morbidity and mortality after anesthesia and surgery (12). Pre-anesthesia and postoperative care to reduce mor-bidity and mortality of patients with hepatic impairment is of particular importance. The use of intravenous anes-thetic drugs, for systemic use in both patients with nor-mal liver function and those with liver disorders, is as-sociated with complications. Choice of anesthetic agent should be based on variables such as proteins bonded to drug, drug metabolism and drug half-life (3-13). There-fore, to choose the right medication in this case, proper-
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ties, metabolism and adverse effects, particularly liver complications of anesthetic and sedative drugs, should be studied. To achieve this goal, we decided to look at rel-evant articles in reliable databases.
2. Evidence AcquisitionTo find the required articles, the best available evidence regarding the use of hypnotic anesthetic agents in liver diseases was used. First, a literature search of systematic reviews, randomized clinical trials and evidence-based medical guidelines was performed and reliable databas-es were used. Search was performed based on keywords including anesthesia, liver dysfunction, hypnotic anes-thetics and general anesthesia in patients with hepatic diseases, hypnotic anesthetics complications and similar words. In this article, only articles published since 1965 were examined and the inclusion and exclusion criteria were as follows:Inclusion criteria:1) Articles that examined the impact and use of hypnot-ic anesthetic drugs in liver diseases2) Articles performed in adults.Exclusion criterion: Articles not published in English.
3. Results
3.1. Overview of anesthesia in hepatic diseaseIn recent years, a significant increase has been occurred in the number of patients with impaired hepatic function or end stage liver disease requiring surgery. In evaluating these patients, anesthesiologists should have sufficient knowledge of the underlying disease and its impact on the performance of other organs, the risks of anesthesia and anesthetic effect on the underlying disease as well. In preoperative evaluation of these patients, probability of hepatic encephalopathy, pleural effusion, cardiomy-opathy in cirrhosis and coagulation disorders should be considered. Using the Child-Turcotte-Pugh and the model for end stage liver disease scores can help anesthesiolo-gists determine the risk of surgery (14). When inducing anesthesia in patients with hepatic disease, close moni-toring should be performed for the patient. Thus, oxy-gen demand and supply should be carefully monitored, which is achieved through precise control of pulmonary ventilation and cardiovascular function. Therefore, in-travascular volume, cardiac output and tissue perfusion pressure should be in the normal range (7).Volatile anesthetics, narcotics and intravenous anes-thetics are well tolerated in liver insufficient patients under control, but caution should be taken in decom-pensated patients, as long-standing effect of drugs, ef-fects on hemodynamics and subsequent encephalopa-thy make it difficult to control anesthesia and prolonged impairment of consciousness after anesthesia (7, 11, 13). If possible, local anesthesia is performed in patients with advanced hepatic diseases. However, it is not allowed in 
patients with coagulopathy diseases (7, 15).Opioids are successfully used in patients with liver dis-eases and in the meantime fentanyl is the drug of choice for these patients when using with average dosage, the oxygen content of the liver and liver blood flow are not affected (14, 16).Among the drugs used for anesthesia induction, propo-fol is the drug of choice in patients with liver diseases (17). As a rule, any type of long-acting anesthetic agent should not be used in patients with cirrhosis. Fentanyl from nar-cotics, lorazepam and oxazepam from sedatives, along with some anesthetic gases such as Sevoflurane or intra-venous anesthetics such as propofol, are recommended in these patients (18-20).
3.2. Hypnotic Agents
3.2.1. BarbituratesBarbiturates, especially thiopental are traditional anes-thetic agents used in the operating room and to a lesser extent in the emergency department. The drug rapidly crosses the blood brain barrier and induces anesthesia in less than a minute and then rapidly absorbed and metabolized in the liver (21). Using a single dosage of thiopental intravenously induces anesthesia for 5 to 10 minutes; this time is 4 to 6 minutes for methohexital (22, 23). Barbiturates advantages include high strength, rapid onset, short duration, a decrease in brain metabolism, reduction in oxygen consumption and a reduction of ce-rebral blood flow and Intracranial Pressure (ICP) (24, 25). Using barbiturates in hypovolemic patients leads to hy-potension and disruption of cerebral perfusion pressure (CPP). The considerable adverse effect of barbiturates is vasomotor center depression and decreased myocardial contractility, which can lead to hypotension and it has been shown that a decrease to an average of 40 mm Hg in Mean Arterial Pressure (MAP) occurs (26).Although barbiturates do not affect the hepatic blood flow, the drug may underlie the development of hepatic encephalopathy by binding to Gamma Amino Butyric Acid (GABA) receptors in the brain; therefore, the drug should be used with caution in patients with liver diseas-es (8). Thiopental metabolism in patients with cirrhosis is reduced, on the other hand, proteins attached to thio-pental are also reduced, and thus, the overall clearance of the drug does not change in patients with cirrhosis (27). This medication should not be used in patients with hepatic impairment and if used the dosage should be re-duced (17, 28). Other adverse effects of the drug include cough, sneezing and hiccups (29). A case of jaundice and hepatitis was reported following the use of thiopental by Hasselstrom in 1979 (29).
3.2.2. EtomidateEtomidate is a water-soluble and fat-soluble carboxyl-ated imidazole anesthetic agent (21, 31). The drug is rap-
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idly hydrolyzed in plasma and liver and excreted in the urine (32). The important advantage of etomidate is the lack of cardiac depression effect (30, 31). Due to the lack of analgesic effects, the drug should be used with pain-killer (21, 32). The most important feature of etomidate in emergency department is the hemodynamically stability with no changes in MAP (33-35). However, slight increase in Heart Rate (HR) occurs (36). Most common adverse ef-fects of etomidate include injection site pain, nausea and vomiting and myoclonic muscle jump (29, 37). Other adverse effects of the drug include hypo and hyperven-tilation, apnea (5 to 90 seconds), tachycardia and brady-cardia (29). The amount of clearance of etomidate in pa-tients with cirrhosis is similar to that of normal patients. However, the distribution volume of the drug in patients with liver cirrhosis is doubled (38).
3.2.3. KetamineKetamine is an anesthetic agent, which gives a dissocia-tive anesthesia, along with analgesia and amnesia while the patient is awake. The medication is used to treat pa-tients severely agitated and with resistant delirium (21). Ketamine is a water and fat soluble drug and easily enters the central nervous system (CNS), and like barbiturates rapidly accumulated and metabolized in the liver (21). The drug adverse effects include increased blood pres-sure, increased heart rate and cardiac output, diplopia, nistagmus, increased intraocular pressure, nausea, vom-iting and anorexia (30). Chronic abuse of ketamine can cause liver fibrosis, common bile duct (CBD) dilatation and microscopic damage to CBD (38-40). In patients re-ceiving Ketamine for infusion chronic pain, several cases of ketamine-related injuries have been reported, as an increase in liver enzymes (approximately 3-fold higher) and takes about three months (41). Due to good analgesia, ketamine is used in patients undergoing colonoscopy, as in the study conducted by Khajavi et al. on 60 patients undergoing colonoscopy sedated with a combination of propofol and ketamine, patient satisfaction was signifi-cantly higher compared to those sedated by a combina-tion of propofol and fentanyl (42).
3.2.4. PropofolPropofol is an anesthetic widely used in emergency department. The drug has alkylphenol composition. An-algesic effects of the drug are slight, but it has amnestic effects (43, 44). Propofol is a lipophilic and water-insolu-ble drug, which is rapidly absorbed by (brain) tissue and quickly spread in fat and muscle and finally metabolized by the liver and excreted through the kidneys (45). Propo-fol is often successfully used in children and adults with refractory status epilepticus (46). In a study by Soleiman-pour et al. on 90 patients with migraine headaches, it was shown that propofol is an effective and safe treatment in these patients (47). Because the drug has a high affinity for GABA receptors and altered and activated physiologi-
cal characteristics of the receptor, it reduces pain (48). It lowers MAP (10 mmHg), thus reducing blood flow to the brain. Other adverse effects include acidosis (metabolic and respiratory), rashes, hives, decreased IOP, injection site pain, seizure-like dystonic movements, nausea, ab-normal taste of mouth felt immediately after injection and acute pancreatitis (29). Propofol infusion syndrome is a rare complication of continuous infusion of propofol when used for more than 48 hours with dose higher than 4 mg/kg/h. The pathophysiology of the complication is unknown, but impaired mitochondrial respiratory chain is involved in creation of syndrome (49). The complica-tion is characterized by metabolic acidosis, rhabdomy-olysis of skeletal muscle and cardiac muscle, arrhyth-mias (bradycardia, atrial fibrillation, supraventricular and ventricular tachycardia, bundle branch block and asystole), heart failure, renal failure, hepatomegaly and death. Continuous propofol infusion syndrome includes extra hepatic and intrahepatic complications. Hepatic complications of the syndrome including hepatomegaly and fatty liver are because of the high fat content of drug (49, 50).Rison and Ko reported a few cases of fatty liver induced by propofol infusion in children with status epilepticus, in which cases had no extra hepatic complications (46). In many texts, propofol has been suggested as the drug of choice for anesthesia in patients with cirrhosis (17-20). In a study conducted by Faga et al. on 240 cases of colonoscopy and ERCP sedated by propofol, it was shown that performing the procedure under sedation by propo-fol had no complications on patients with and without cirrhosis (51). The incidence of hepatic encephalopathy caused by endoscopy has not been reported with seda-tion by propofol in patients with cirrhosis (52, 53). Asai and Yagi described a case of liver injury induced by re-peated injections of propofol in a patient with psychiat-ric disease treated with electro-shock (54). Sedation by propofol in the treatment of intracranial hypertension caused by fulminant hepatic failure improves survival of these patients (55).
3.2.5. Benzodiazepines (midazolam)Benzodiazepines as anti-anxiety, sedative, amnestic, hypnotic, anticonvulsant and muscle relaxant drugs are widely used. However, these drugs have no analgesic ef-fect. Midazolam is a suitable alternative to diazepam in induction of anesthesia, especially in elderly patients, because of higher strength and shorter duration of ac-tion and also less cardiorespiratory depression (56). Midazolam accumulates in adipose tissue outside the CNS resulting in fewer CNS adverse effects. Midazolam adverse effects are like other benzodiazepines includ-ing a slight increase in heart rate and a slight decrease in systolic blood pressure that is aggravated in hypovo-lemic condition. Respiratory depression is an adverse ef-fect of the medication, especially in cases of high doses 
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and high-speed injection. In contrast to diazepam and chlordiazepoxide that increase hepatic metabolism, ox-azepam and lorazepam glucoronized without hepatic metabolism are preferred (57). Park explained an acute liver failure due to the use of diazepam; it has been suc-cessfully treated in cats (58). Taking oral combination of lorazepam and tramadol before hepatic biopsy clear-ly reduces pain caused by biopsy (59).
3.2.6. Opioids (Fentanyl)Fentanyl is a synthetic opioid used widely since 1968. The pharmacological effects of the drug include rapid clearance, high strength and less histamine release (60). Fentanyl passes blood-brain barrier rapidly, cre-ates an analgesic effect in less than two minutes and quickly reduces serum levels of the drug in the body. The use of fentanyl causes less nausea and hypotension than other opioids (61). It causes muscle rigidity of the chest wall and diaphragm; the effect is more significant in cases of doses higher than 15 micrograms per kilo-gram of body weight and rapid injection of the drug (62). Another complication of fentanyl is respiratory depression, which is aggravated when used along with other CNS depressant drugs (63)According to Zhao and Shen, remifentanil prevents liver damage due to ischemia by reducing apoptosis (64). Fentanyl, sufentanil and remifentanil are anes-thesia drugs of choice in patients with liver failure. Due to decreased hepatic blood flow, metabolism of morphine and meperidine in patients with liver dys-function and portal hypertension is greatly decreased, and fentanyl and sufentanil are preferred over these two drugs (8).
4. DiscussionAnesthesia in patients with cirrhosis and liver dis-orders is a challenging issue doubled by the use of systemic intravenous drugs. Many drugs used in anes-thesia have hepatic metabolism, thus the use of these drugs in patients with impaired liver function should be cautious and anesthesiologist must be aware of metabolism pathway and adverse effects of anesthetic drugs to choose the best and the safest drug for these patients. Opioids are successfully used in patients with liver diseases and Fentanyl is the drug of choice for these patients. As the average dosage of drug is used, oxygen content of the liver and liver blood flow is not affected (14, 16). Among the drugs used for induction of anesthesia, propofol is the drug of choice in patients with liver diseases (17). As a rule, any type of long-acting local anesthetic in patients with cirrhosis should be avoided. Fentanyl from narcotics, lorazepam and oxaz-epam from sedatives along with some volatile anesthet-ic agent such as Sevoflurane or intravenous anesthetics such as propofol, are recommended in these patients (18-20).
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